Literature DB >> 31152253

What's New in Rezum: a Transurethral Water Vapour Therapy for BPH.

Zachary Green1, Jennifer Westwood2, Bhaskar K Somani1,3.   

Abstract

PURPOSE OF REVIEW: Rezum is a new minimally invasive treatment for benign prostate enlargement using thermal transurethral water vapour therapy. We review the evidence with advantages and disadvantages of this technique. RECENT
FINDINGS: There are five studies reported including a randomised control trial looking at the outcomes of Rezum. The outcomes show an IPSS reduction by 45-60%, QoL improvement with a score reduction of 37-59%, the Qmax improvement by 44-72% and the PVR reduction by 20-38%. Convective water vapour therapy using the Rezum system has been shown to have successful outcomes in the treatment of LUTS resulting from BPH. The reported complications are infrequent and often minor, and it seems to be relatively cost-effective.

Entities:  

Keywords:  BPH; LUTS; Minimally invasive therapy; Rezum; TURP; Water vapour therapy

Mesh:

Substances:

Year:  2019        PMID: 31152253     DOI: 10.1007/s11934-019-0903-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  2 in total

1.  Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.

Authors:  Giampaolo Siena; L Cindolo; G Ferrari; D Maruzzi; G Fasolis; S V Condorelli; F Varvello; F Visalli; S Rabito; S Toso; S Caroassai; A Mari; L Viola; B K Somani; M Carini
Journal:  World J Urol       Date:  2021-03-31       Impact factor: 4.226

2.  Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes.

Authors:  Evan B Garden; Devki Shukla; Krishna T Ravivarapu; Steven A Kaplan; Avinash K Reddy; Alexander C Small; Michael A Palese
Journal:  World J Urol       Date:  2021-01-03       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.